EC Clinical and Medical Case Reports

Research Article Volume 6 Issue 5 - 2023

International Normalized Ratio Variability around Holidays and Predictors of Poor Time in Therapeutic Range in Patients Treatment with Warfarin

David J Silva1, Ravi Mandapati2 and Huyentran N Tran3*

1Pharmacist, Department of Pharmacy Services, Yale New Haven Hospital, New Haven, CA, USA

2Professor of Medicine and Pediatrics, Director, Loma Linda University International Heart Institute, Loma Linda University Medical Center, Loma Linda, CA, USA

3Associate Professor, Department of Pharmacy Practice, School of Pharmacy, Loma Linda University, Loma Linda, CA, USA

*Corresponding Author: Huyentran N Tran, Associate Professor, Department of Pharmacy Practice, School of Pharmacy, Loma Linda University, Loma Linda, CA, USA.
Received: April 18, 2023; Published: April 26, 2023




Warfarin has long been the standard-of-care anticoagulant in treating and preventing thromboembolic events in a range of conditions, most commonly for atrial fibrillation (AF) [1]. However, Direct Oral Anticoagulant (DOAC) use has risen significantly in recent years, with a shift from 7.4% to 66.8% from 2011 to 2019 among Medicare Part D beneficiaries taking oral anticoagulants. Despite the increasing use of DOACs, warfarin is still often used in patients who may be poor DOAC candidates due to renal or hepatic impairment, extremes of body weight, drug interactions, or for conditions in which DOAC efficacy and safety is sub-optimal or has not been well-established [2].

Keywords: Warfarin; Atrial Fibrillation (AF); Direct Oral Anticoagulant (DOAC)

  1. Troy A and Anderson TS. “National Trends in Use of and Spending on Oral Anticoagulants Among US Medicare Beneficiaries From 2011 to 2019”. JAMA Health Forum7 (2021): e211693.
  2. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges (2022).
  3. Ta Michael Lee M and Klein TE. “Pharmacogenetics of warfarin: challenges and opportunities”. Journal of Human Genetics6 (2013): 334-338.
  4. Rosendaal FR., et al. “A method to determine the optimal intensity of oral anticoagulant therapy”. Journal of Thrombosis and Haemostasis3 (1993): 236-239.
  5. Siddiqui S., et al. “Variability in the Calculation of Time in Therapeutic Range for the Quality Control Measurement of Warfarin”. Innovations in Cardiac Rhythm Management12 (2018): 3428-3434.
  6. Vestergaard AS., et al. “The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis”. PLOS ONE11 (2017): e0188482.
  7. Erkens PMG., et al. “Benchmark for Time in Therapeutic Range in Venous Thromboembolism: A Systematic Review and Meta-Analysis”. PLoS ONE9 (2012): e42269.
  8. Haas S., et al. “Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry”. PloS One10 (2016): e0164076.
  9. Connolly SJ., et al. “Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range”. Circulation 20 (2008): 2029-2037.
  10. Recommendations | Atrial fibrillation: diagnosis and management | Guidance | NICE (2022).
  11. Antithrombotic Therapy for Atrial Fibrillation. Chest (2022).
  12. Hindricks G., et al. “2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC”. European Heart Journal5 (2021): 373-498.
  13. Gateman D., et al. “Time in therapeutic range: Warfarin anticoagulation for atrial fibrillation in a community-based practice”. Canadian Family Physician10 (2017): e425-e431.
  14. Rose AJ., et al. “Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA)”. Journal of Thrombosis and Haemostasis10 (2010): 2182-2191.
  15. Rose AJ., et al. “Risk-Adjusted Percent Time in Therapeutic Range as a Quality Indicator for Outpatient Oral Anticoagulation”. Circulation: Cardiovascular Quality and Outcomes1 (2011): 22-29.
  16. Razouki Z., et al. “Pathways to poor anticoagulation control”. Journal of Thrombosis and Haemostasis5 (2014): 628-634.
  17. Apostolakis S., et al. “Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score”. Chest5 (2013): 1555-1563.
  18. Farsad BF., et al. “Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study”. Journal of Clinical and Diagnostic Research9 (2016): FC04-FC06.
  19. Lin KJ., et al. “Prediction Score for Anticoagulation Control Quality Among Older Adults”. Journal of the American Heart Association10 (2017): e006814.
  20. Penning-van Beest FJA., et al. “Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants”. Journal of Thrombosis and Haemostasis2 (2008): 284-290.
  21. Salobir B., et al. “Intensity of Long-Term Treatment with Warfarin Is Influenced by Seasonal Variations”. Pathophysiology of Haemostasis and Thrombosis4 (2002): 151-154.
  22. Van Patot MCT., et al. “Risk of impaired coagulation in warfarin patients ascending to altitude (>2400 m)”. High Altitude Medicine and Biology1 (2006): 39-46.
  23. Ringwald J., et al. “Travel and Oral Anticoagulation”. Journal of Travel Medicine4 (2009): 276-283.
  24. Charlson ME., et al. “A new method of classifying prognostic comorbidity in longitudinal studies: development and validation”. Journal of Chronic Diseases5 (1987): 373-383.
  25. ACS Profile Report: 2015-2019 / Missouri Census Data Center (2022).
  26. Bureau UC. 2010-2014 ACS 5-year Estimates Census (2022).
  27. Using the Rosendaal method for calculating Therapeutic Time in Range (TTR) (2022).
  28. IBM SPSS Statistics for Windows. Armonk, NY: IBM Corp.: IBM Corp (2016).
  29. Bursac Z., et al. “Purposeful selection of variables in logistic regression”. Source Code for Biology and Medicine1 (2008): 17.
  30. Mannucci PM., et al. “Multimorbidity and polypharmacy in the elderly: lessons from REPOSI”. Internal and Emergency Medicine7 (2014): 723-734.
  31. Pokorney SD., et al. “Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry”. American Heart Journal1 (2015): 141-148.
  32. McAlister FA., et al. “Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada”. BMJ Open1 (2018): e016980.
  33. Proietti M., et al. “Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial”. Clinical Research in Cardiology European Society of Cardiology5 (2016): 412-420.
  34. Guidelines for medical treatment and its safety in the elderly (2022).
  35. Rouaud A., et al. “Comorbidities against Quality Control of VKA Therapy in Non-Valvular Atrial Fibrillation: A French National Cross-Sectional Study”. PLoS ONE3 (2015): e0119043.
  36. Dlott JS., et al. “National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation”. Circulation13 (2014): 1407-1414.
  37. Abohelaika S., et al. “Impact of age on long‐term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient management”. British Journal of Clinical Pharmacology4 (2016): 1076-1083.
  38. Marcatto LR., et al. “Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation”. Oncotarget34 (2016): 54194-54199.
  39. Witt DM., et al. “Outcomes and predictors of very stable INR control during chronic anticoagulation therapy”. Blood5 (2009): 952-956.
  40. Sevilla-Cazes J., et al. “Association Between Patient-Reported Medication Adherence and Anticoagulation Control”. The American Journal of Medicine9 (2017): 1092-1098.

Huyentran N Tran., et al. "International Normalized Ratio Variability around Holidays and Predictors of Poor Time in Therapeutic Range in Patients Treatment with Warfarin." EC Clinical and Medical Case Reports   6.5 (2023): 43-52.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net